Michael D. Schneider
Directeur/Membre du Conseil chez The Medical Research Council
Profil
Michael D.
Schneider was the founder of Kardia Therapeutics, Inc. founded in 2002, where he held the title of Director from 2002 to 2010.
Currently, he is a Director at The Medical Research Council.
Previously, he held the position of Director-Centre for Research Excellence at British Heart Foundation, was a Professor at Baylor College of Medicine from 1984 to 2010, and was the Head-Cardiovascular Science at The National Heart & Lung Institute.
Dr. Schneider earned his doctorate degree from the University of Pennsylvania in 1976.
Postes actifs de Michael D. Schneider
| Sociétés | Poste | Début |
|---|---|---|
The Medical Research Council
 The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Directeur/Membre du Conseil | 12/07/2011 |
Anciens postes connus de Michael D. Schneider
| Sociétés | Poste | Fin |
|---|---|---|
| British Heart Foundation | Corporate Officer/Principal | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
The National Heart & Lung Institute
 The National Heart & Lung Institute Miscellaneous Commercial ServicesCommercial Services The National Heart & Lung Institute provided medical educational services. The company was headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Kardia Therapeutics, Inc.
 Kardia Therapeutics, Inc. BiotechnologyHealth Technology Kardia Therapeutics, Inc. develops cardiac regenerative therapies. It focuses in the areas of myocardial infarction and heart failure. The firm's portfolio of technologies utilizes three related approaches which include adult cardiac progenitor cells, stem cell optimization technologies, and homing/growth factor therapies. The company was founded by Michael D. Schneider and Robert J. Schwartz in 2002 and is headquartered in Houston, TX. | Fondateur | - |
Formation de Michael D. Schneider
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Kardia Therapeutics, Inc.
Kardia Therapeutics, Inc. BiotechnologyHealth Technology Kardia Therapeutics, Inc. develops cardiac regenerative therapies. It focuses in the areas of myocardial infarction and heart failure. The firm's portfolio of technologies utilizes three related approaches which include adult cardiac progenitor cells, stem cell optimization technologies, and homing/growth factor therapies. The company was founded by Michael D. Schneider and Robert J. Schwartz in 2002 and is headquartered in Houston, TX. | Health Technology |
The National Heart & Lung Institute
The National Heart & Lung Institute Miscellaneous Commercial ServicesCommercial Services The National Heart & Lung Institute provided medical educational services. The company was headquartered in London, the United Kingdom. | Commercial Services |
| British Heart Foundation | Commercial Services |
The Medical Research Council
The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Commercial Services |
